- 米国企業
- Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc.AVTE
| 2021年 12月31日 | 2022年 12月31日 |
---|
Cash and cash equivalents | 54 | 22 |
---|
Short-term investments | 113 | 107 |
---|
Prepaid expenses and other current assets | 7 | 2 |
---|
Total current assets | 174 | 131 |
---|
Property and equipment, net | 0 | 0 |
---|
Operating lease right-of-use asset | 1 | 1 |
---|
Other long-term assets | 0 | 3 |
---|
Total assets | 175 | 135 |
---|
Accounts payable | 1 | 3 |
---|
Accrued and other current liabilities | 1 | 5 |
---|
Current | 0 | 0 |
---|
Total current liabilities | 3 | 8 |
---|
Non-current | 0 | 1 |
---|
Other liabilities | 0 | 0 |
---|
Total liabilities | 3 | 9 |
---|
Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 24,722,974 and 24,410,393 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 0 | 0 |
---|
Additional paid-in capital | 209 | 215 |
---|
Accumulated other comprehensive loss | -0 | -0 |
---|
Accumulated deficit | -36 | -88 |
---|
Total stockholders' equity | 172 | 127 |
---|
Total liabilities and stockholders' equity | 175 | 135 |
---|